Pharmaceutical firm BioNTech has struck a deal with the United Kingdom to develop a cancer vaccine, with cancer vaccine trials expected to start as early as September.
BioNTech, a company founded by Turkish German immigrants that is famed for its COVID-19 vaccine, announced that it has started clinical trials for a malaria vaccine, according to Anadolu Agency. Phase 1 trial of the BNT165b1 vaccine will enroll around 60 healthy
mRNA technology transforms the human body into a virus-zapping vaccine factory, teaching cells how to make a protein that triggers an immune response against viruses
BioNTech SE (NASDAQ:NASDAQ:BNTX) Q3 2022 Earnings Conference Call November 07, 2022 08:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations & Strategy Ugur.